Story thread · 10 reports / 8 sources
STAT+: After failure of Angelman syndrome drug, experts see hope in other experimental therapies
statnews.com · 10d
How the coverage leans
Across 8 sources · syndicated copies counted once
After the failure of an experimental drug for Angelman syndrome, experts cautioned that there is still reason to think similar experimental medicines can succeed.
First report: STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial — statnews.com, 12d
The coverage
- Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder
medcitynews.com · 11d
- Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop.
finance.yahoo.com · 11d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.